eligibility_summary
Adults ≥18 with confirmed advanced/metastatic CRC, measurable disease, ECOG 0–1, life expectancy ≥12 wks, not pregnant. Escalation: progressed/intolerant, expansion: untreated. Exclusions: prior B7‑H3/topo‑I ADCs, recent anticancer therapy/radiation/surgery, CNS mets, CYP3A4 or QT‑prolonging drugs, unresolved >G2 AEs, major organ/CV/infectious/immune/hepatic (Child‑Pugh B+)/pulmonary/bleeding/thrombotic/neuro‑psychiatric disease, pregnancy/lactation, allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
ARTEMIS-102 (Phase Ib) evaluates HS-20093 combinations in advanced metastatic colorectal cancer. HS-20093 is a fully humanized IgG1 antibody-drug conjugate targeting B7-H3 (CD276) on tumor cells, binding leads to internalization and delivery of a cytotoxic payload, with potential Fc-mediated effector activity. Combinations include HS-20093 + bevacizumab alone or with fluoropyrimidine backbones: 5‑FU/leucovorin, capecitabine, and FOLFOX (oxaliplatin + 5‑FU/leucovorin). Mechanisms: bevacizumab is an anti‑VEGF‑A monoclonal antibody blocking angiogenesis, 5‑FU (and prodrug capecitabine) is an antimetabolite inhibiting thymidylate synthase, leucovorin enhances 5‑FU’s TS binding, oxaliplatin forms DNA crosslinks. Targets/pathways: B7-H3–expressing tumor cells/microenvironment, VEGF-driven endothelial angiogenesis, and tumor DNA synthesis/repair.